Transcept resubmits middle-of-the-night sleep drug to FDA

Transcept Pharmaceuticals Inc. resubmitted its middle-of-the-night sleep drug to federal regulators, two months after the drug was rejected, the company said Tuesday.
The Richmond company (NASDAQ: TSPT) earlier this month said that it planned to resubmit the drug, called Intermezzo, by the end of September. The Food and Drug Administration has said its review of the new application could take as little as two months.